Obagi Medical Products, Inc. (OMPI) announced the publication of a study of its copper-zinc malonate eye treatment ELASTIderm(TM) in the September 2008 issue of Experimental Dermatology, a premier journal of investigative dermatology. The results of the study suggest that six weeks of treatment with ELASTIderm can enhance the biosynthesis of elastin in skin.
Periorbital skin biopsies were obtained from female subjects, with photoaged skin, who participated in a randomized, double-blind, multi-center study evaluating the clinical effects of ELASTIderm eye treatment. Results from the histological analyses suggest that repair and regeneration of the elastic fiber network occurred during the 6 weeks of treatment with ELASTIderm. Regeneration of the elastic fiber network is thought to be due to reduced degradation of the elastic fibers or enhanced biosynthesis of tropoelastin, the precursor molecule of elastin.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index